Ultragenyx Pharmaceutical RARE Liability Related To Sale Of Future Royalties
Liability Related To Sale Of Future Royalties at other companies
Other financials
Where this comes from
Reported directly by Ultragenyx Pharmaceutical in its filing.
Tagged under the XBRL concept rare:LiabilityRelatedToSaleOfFutureRoyalties.
The official record: Ultragenyx Pharmaceutical’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ultragenyx Pharmaceutical's liability related to sale of future royalties.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ultragenyx Pharmaceutical's liability related to sale of future royalties?
- Ultragenyx Pharmaceutical (RARE) reported liability related to sale of future royalties of $1.13B in Q1 2026.
- How has Ultragenyx Pharmaceutical's liability related to sale of future royalties changed year-over-year?
- Ultragenyx Pharmaceutical's liability related to sale of future royalties increased by 42.1% year-over-year, from $794.05M to $1.13B.
- What is the long-term trend for Ultragenyx Pharmaceutical's liability related to sale of future royalties?
- Over 5 years (2020 to 2025), Ultragenyx Pharmaceutical's liability related to sale of future royalties has grown at a 27.9% compound annual growth rate (CAGR), from $335.67M to $1.15B.
- What does liability related to sale of future royalties mean?
- This represents the long-term portion of financial obligations resulting from the upfront sale of rights to future royalty payments. It serves as a measure of the total outstanding debt-like commitment owed to investors who provided capital in exchange for a share of future product revenue. Investors monitor this to understand the long-term impact of royalty monetization on future earnings and the company's overall leverage profile.